# Puberty-Onset Selective Mutism in a Female Adolescent With Autism Spectrum Disorder

**Authors:** Tiago Soares, Joana Coelho Santos, Daniela Couto

PMC · DOI: 10.7759/cureus.82280 · Cureus · 2025-04-15

## TL;DR

A teenage girl with autism developed selective mutism during puberty and after major life changes, and she improved with a combination of therapy and medication.

## Contribution

This case highlights atypical anxiety presentations in adolescents with autism and the effectiveness of individualized, multimodal interventions.

## Key findings

- Selective mutism emerged during puberty and major life transitions in an adolescent with autism.
- A combination of cognitive behavioral therapy and medication led to remission of symptoms.
- The case emphasizes the need for early and tailored interventions for anxiety in individuals with autism.

## Abstract

Selective mutism (SM) is a rare anxiety disorder typically diagnosed in early childhood. It is characterized by a persistent failure to speak in specific social situations despite having the ability to verbalize in others. Although the onset of SM during adolescence is uncommon, its emergence during puberty or major life transitions may reflect an atypical form of anxiety that is more frequently observed in individuals with autism spectrum disorder (ASD). We describe a case of an 11-year-old girl who developed SM following the onset of puberty and significant environmental changes, including school transition and relocation. She was subsequently diagnosed with ASD. A multidisciplinary treatment approach involving cognitive behavioral therapy, fluoxetine, and pregabalin led to complete remission of SM and marked improvements in academic and social functioning. This case underscores the importance of recognising atypical anxiety presentations in adolescents with ASD and highlights the value of early, individualized, and multimodal interventions. It also raises ethical considerations regarding the temporary use of covert medication in cases with severe resistance to treatment.

## Linked entities

- **Chemicals:** fluoxetine (PubChem CID 3386), pregabalin (PubChem CID 4715169)
- **Diseases:** autism spectrum disorder (MONDO:0005258)

## Full-text entities

- **Diseases:** delusional disorder (MESH:D012563), inhibited (MESH:C565433), joint hypermobility (MESH:D007593), Anxiety Related Emotional Disorders (MESH:D001008), cognitive inflexibility (MESH:D003072), extrapyramidal symptoms (MESH:D001480), learning difficulties (MESH:D007859), involuntary saccadic eye movements (MESH:C537310), ASD (MESH:D000067877), panic disorder (MESH:D016584), mood disturbance (MESH:D019964), impairment of functional language (MESH:D007806), headaches (MESH:D006261), fatigue (MESH:D005221), social anxiety disorder (MESH:D000072861), excoriation behaviors (MESH:D001523), behavioral rigidity (MESH:D009127), sensory overload (MESH:D019190), hypersensitivity (MESH:D004342), diplopia (MESH:D004172), COVID-19 (MESH:D000086382), disorder of intellectual development (MESH:D008607), Alzheimer's disease (MESH:D000544), tics (MESH:D020323), anxiety (MESH:D001007), obsessions (MESH:D009771), psychotic symptoms (MESH:D011618), nausea (MESH:D009325), communication deficits (MESH:D003147), Separation Anxiety Disorder (MESH:D001010), SM (MESH:D009155), agitation (MESH:D011595), self-harm (MESH:D012652), dizziness (MESH:D004244), Autism (MESH:D001321)
- **Chemicals:** Clonazepam (MESH:D002998), risperidone (MESH:D018967), Pregabalin (MESH:D000069583), loflazepate (MESH:C040581), Fluoxetine (MESH:D005473), water (MESH:D014867), mexazolam (MESH:C014262), alprazolam (MESH:D000525), Aripiprazole (MESH:D000068180)
- **Species:** Homo sapiens (human, species) [taxon 9606], Oryza sativa (Asian cultivated rice, species) [taxon 4530]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12079171/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12079171/full.md

## References

19 references — full list in the complete paper: https://tomesphere.com/paper/PMC12079171/full.md

---
Source: https://tomesphere.com/paper/PMC12079171